Inflammatory Bowel Disease
IBD sgi Diagnostic is evolving to IBD Precis
IBD sgi Diagnostic was Prometheus Laboratories’ 4th-generation diagnostic test for inflammatory bowel disease (IBD) combining serologic, genetic and inflammation markers with a proprietary algorithm to help differentiate IBD from non-IBD and ulcerative colitis (UC) from Crohn’s disease (CD).
IBD Precis™ is now available, representing the 5th generation in the continuous evolution of our IBD diagnostic solutions. To ensure a smooth transition, IBD sgi Diagnostic will remain available until March 31, 2026. This advancement leverages novel serologic markers that not only aid in differentiating IBD from non-IBD and CD from UC, but also help to risk stratify disease and non-invasively indicate potential colonic and/or ileal involvement.
IBD Precis is the start of the Prometheus continuum of care for IBD patients
IBD sgi Diagnostic and IBD Precis are laboratory-developed tests that were developed, and analytically and clinically validated by Prometheus Laboratories Inc. under federal Clinical Laboratory Improvement Amendments (CLIA) guidelines, and are performed exclusively in our high complexity CLIA certified (05D0917432) and College of American Pathologists (CAP) accredited (6805501) clinical laboratory. As laboratory developed tests, they have not been cleared or approved by the US FDA. The test may be covered by one or more US pending or issued patents – see prometheuslabs.com/patents. This material is provided for general information purposes only, as an educational service for healthcare providers. It is not intended as a substitute for medical advice and/or consultation with a physician.